This is encouraging early clinical data but from only a handful of patients without reported statistics. The stock may react positively on the survival and recovery signals, but de-risking is marginal until larger randomized data drop in early 2027. Expect volatility; consider positioning for the next data readout rather than chasing the initial pop.
Price Chart
Executive Summary
MiNK Therapeutics presented initial Phase 2 data at MHSRS showing first patients treated with agenT-797 for severe hypoxemic pneumonia were alive and afebrile at Day 28 with improved oxygenation, infection control, and removal from ventilator/vasopressor support. Biological signals included reduced inflammation and increased tissue repair markers. Enrollment continues in Ukraine with U.S. sites opening; additional data expected in early 2027. For a $58M market cap company, these early observations are positive but not statistically significant given tiny patient numbers and no placebo comparison yet.
Key Facts
- First patients treated with agenT-797 were alive and afebrile at Day 28 with improved oxygenation and infection control.
- Patients removed from ventilator and vasopressor support.
- No major serious adverse events attributed to agenT-797 reported in these first treated patients.
- Biological changes associated with immune recovery, epithelial repair, and pulmonary vascular recovery observed.
- Randomized Phase 2 trial (C-1300-02) ongoing in Lviv, Ukraine; U.S. sites opening.
- Additional data expected in early 2027.
- agenT-797 is off-the-shelf, no apheresis, patient-specific manufacturing, HLA matching, or lymphodepletion required.
- MiNK has a $58M market cap.
Financial Impact
Not disclosed in press release; no financial data provided.
Risk Factors
- Very early-stage data from few patients — not statistically significant.
- Placebo-controlled arm not reported yet; high risk of no benefit in randomized portion.
- Next major data not expected until early 2027 — long wait with no near-term catalyst.
- Clinical-stage biotech with no approved products or revenue — binary outcome risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3340551 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 7w ago | 8-K | $11.00 $12.00 | ▲ +9.09% | ▲ +10.84% | $12.44 (+13.09%) |
Aug 13, 2026 7w ago | Press Release | $11.00 $12.00 | ▲ +9.09% | ▲ +10.84% | $12.44 (+13.09%) |
Aug 6, 2026 8w ago | Press Release | $11.00 $11.23 | ▲ +2.09% | ▲ +1.49% | $12.44 (+13.09%) |
May 28, 2026 18w ago | Press Release | $12.20 $11.64 | ▼ −4.59% | ▼ −1.45% | $12.44 (+1.97%) |
May 20, 2026 19w ago | Press Release | $10.72 $12.14 | ▲ +13.25% | ▲ +12.51% | $12.44 (+16.04%) |
May 15, 2026 20w ago | 8-K | $10.72 $12.54 | ▲ +16.93% | ▲ +14.81% | $12.44 (+16.04%) |
May 15, 2026 20w ago | Press Release | $10.72 $12.54 | ▲ +16.93% | ▲ +14.81% | $12.44 (+16.04%) |
May 14, 2026 20w ago | Press Release | $10.51 $12.02 | ▲ +14.37% | ▲ +15.23% | $12.44 (+18.36%) |
May 12, 2026 20w ago | Press Release | $11.41 $12.19 | ▲ +6.84% | ▲ +8.56% | $12.44 (+9.03%) |
May 8, 2026 20w ago | Press Release | $10.95 $11.82 | ▲ +7.95% | ▲ +8.25% | $12.44 (+13.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access